Cargando…
Current and future management of recurrent respiratory papillomatosis
OBJECTIVES: Recurrent respiratory papillomatosis (RRP) is a chronic disease of the respiratory tract that occurs in both children and adults. It is caused by the human papillomavirus (HPV), in particular low‐risk HPV6 and HPV11, and aggressiveness varies among patients. RRP remains a chronic disease...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824106/ https://www.ncbi.nlm.nih.gov/pubmed/29492465 http://dx.doi.org/10.1002/lio2.132 |
_version_ | 1783301984400441344 |
---|---|
author | Ivancic, Ryan Iqbal, Hassan deSilva, Brad Pan, Quintin Matrka, Laura |
author_facet | Ivancic, Ryan Iqbal, Hassan deSilva, Brad Pan, Quintin Matrka, Laura |
author_sort | Ivancic, Ryan |
collection | PubMed |
description | OBJECTIVES: Recurrent respiratory papillomatosis (RRP) is a chronic disease of the respiratory tract that occurs in both children and adults. It is caused by the human papillomavirus (HPV), in particular low‐risk HPV6 and HPV11, and aggressiveness varies among patients. RRP remains a chronic disease that is difficult to manage. This review provides perspectives on current and future management of RRP. RESULTS: The current standard of care is surgical excision, with adjuvant therapies as needed. Surgical management of RRP has evolved with the introduction of microdebriders and photoangiolytic lasers; the latter can now be used in the office setting. Numerous adjuvant pharmacologic therapies have been utilized with some success. Also, exciting preliminary data show that HPV vaccines may prolong the time to recurrence in the RRP population. There is also optimism that wide‐spread HPV vaccination could reduce RRP incidence indirectly by preventing vertical HPV transmission to newborns. CONCLUSION: To date, the biology of RRP is not well understood, although it has been noted to become more aggressive in the setting of immune suppression. Additional research is needed to better understand immune system dysfunction in RRP such that immunomodulatory approaches may be developed for RRP management. LEVEL OF EVIDENCE: 4 |
format | Online Article Text |
id | pubmed-5824106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-58241062018-02-28 Current and future management of recurrent respiratory papillomatosis Ivancic, Ryan Iqbal, Hassan deSilva, Brad Pan, Quintin Matrka, Laura Laryngoscope Investig Otolaryngol General Otolaryngology OBJECTIVES: Recurrent respiratory papillomatosis (RRP) is a chronic disease of the respiratory tract that occurs in both children and adults. It is caused by the human papillomavirus (HPV), in particular low‐risk HPV6 and HPV11, and aggressiveness varies among patients. RRP remains a chronic disease that is difficult to manage. This review provides perspectives on current and future management of RRP. RESULTS: The current standard of care is surgical excision, with adjuvant therapies as needed. Surgical management of RRP has evolved with the introduction of microdebriders and photoangiolytic lasers; the latter can now be used in the office setting. Numerous adjuvant pharmacologic therapies have been utilized with some success. Also, exciting preliminary data show that HPV vaccines may prolong the time to recurrence in the RRP population. There is also optimism that wide‐spread HPV vaccination could reduce RRP incidence indirectly by preventing vertical HPV transmission to newborns. CONCLUSION: To date, the biology of RRP is not well understood, although it has been noted to become more aggressive in the setting of immune suppression. Additional research is needed to better understand immune system dysfunction in RRP such that immunomodulatory approaches may be developed for RRP management. LEVEL OF EVIDENCE: 4 John Wiley and Sons Inc. 2018-01-14 /pmc/articles/PMC5824106/ /pubmed/29492465 http://dx.doi.org/10.1002/lio2.132 Text en © 2018 The Authors Laryngoscope Investigative Otolaryngology published by Wiley Periodicals, Inc. on behalf of The Triological Society This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | General Otolaryngology Ivancic, Ryan Iqbal, Hassan deSilva, Brad Pan, Quintin Matrka, Laura Current and future management of recurrent respiratory papillomatosis |
title | Current and future management of recurrent respiratory papillomatosis |
title_full | Current and future management of recurrent respiratory papillomatosis |
title_fullStr | Current and future management of recurrent respiratory papillomatosis |
title_full_unstemmed | Current and future management of recurrent respiratory papillomatosis |
title_short | Current and future management of recurrent respiratory papillomatosis |
title_sort | current and future management of recurrent respiratory papillomatosis |
topic | General Otolaryngology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5824106/ https://www.ncbi.nlm.nih.gov/pubmed/29492465 http://dx.doi.org/10.1002/lio2.132 |
work_keys_str_mv | AT ivancicryan currentandfuturemanagementofrecurrentrespiratorypapillomatosis AT iqbalhassan currentandfuturemanagementofrecurrentrespiratorypapillomatosis AT desilvabrad currentandfuturemanagementofrecurrentrespiratorypapillomatosis AT panquintin currentandfuturemanagementofrecurrentrespiratorypapillomatosis AT matrkalaura currentandfuturemanagementofrecurrentrespiratorypapillomatosis |